Sydney, Australia 5 April 2022
Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that Dr Andrei Iagaru has joined Clarity’s Scientific Advisory Board (SAB).
Dr Iagaru is a Professor of Radiology – Nuclear Medicine and the Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford University. His research focus includes PET/MRI and PET/CT imaging for early cancer detection as well as peptide-based diagnostic imaging and therapy. Dr Iagaru is also passionate about clinical translation of novel PET radiopharmaceuticals.
Clarity’s Executive Chairman, Dr Alan Taylor, commented, “We are very pleased to welcome Dr Iagaru to our SAB. His experience with the translation of innovative radiopharmaceutical products to the clinic and expertise in the nuclear medicine field will be a highly valued addition to our Company in pursuit of our ultimate goal of developing next-generation radiopharmaceutical products to improve treatment outcomes for children and adults with cancer. Of particular relevance is Dr Iagaru’s unique knowledge and involvement in the development of two prostate cancer products, Bombesin and Prostate Specific Membrane Antigen (PSMA), both of which are currently in clinical development by Clarity as stand-alone diagnostics as well as theranostics under the Targeted Copper Theranostics (TCT) platform.”
Since joining the faculty at Stanford in 2007, Dr. Iagaru has received several awards including the Society of Nuclear Medicine (SNM) 2009 Image of the Year Award; AuntMinnie 2016 Best Radiology Image, American College of Nuclear Medicine (ACNM) Mid-Winter Conference 2010 Best Essay Award; 2009, 2014 and 2015 Western Regional SNM Scientist Award; 2011 SNM Nuclear Oncology Council Young Investigator Award; and the 2020 Sanjiv Sam Gambhir Distinguished Scientist Award, Western Regional SNM. Dr. Iagaru published more than 200 papers in peer-reviewed journals, as well as 7 book chapters and 1 book.
Dr Andrei Iagaru commented on his appointment, “Clarity has made significant progress in translating and progressing its TCT platform of products in the clinic in recent years. I am excited to join Clarity’s Advisory Board and discover ways in which we can further enhance the radiopharmaceutical field together, developing novel targeted therapies as well as improved diagnostic options for oncology.”
Dr Taylor said, “As Clarity is actively advancing its pipeline of TCT products in the clinic, we want to continue to grow our team, including collaborators and advisers, with people who bring a unique combination of knowledge and expertise and are forefront experts and thought leaders in the field of radiopharmaceuticals. We are committed to developing next generation theranostics that are at the highest standard in the field and address issues with the current generation of radiopharmaceutical products, including clinical as well as manufacturing and logistical challenges, in order to be able to deliver potentially lifesaving treatments to patients and their treating staff around the world on time and at a convenient location.”
This announcement has been authorised for release by the Executive Chairman.
Media Contact
Dr Alan Taylor
Executive Chairman
+61 (0)413 871 165
ataylor@claritypharm.com
About Clarity
Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.
